Rigel Pharmaceuticals | RIGL - Gastos De Venta Y Administración





Gastos De Venta Y Administración Cambio Fecha
Agenus USD 6.21M 4.34M 2026-03
Amgen USD 1.72B 134M 2026-06
Anika Therapeutics USD 10.01M 14K 2025-12
Arrowhead Research USD 46.63M 4.88M 2026-06
AstraZeneca USD 5.8B 735M 2026-06
BioMarin Pharmaceutical USD 395.55M 137.27M 2026-06
Bristol-Myers Squibb USD 1.83B 209M 2026-06
Celldex Therapeutics USD 13.1M 1.65M 2026-06
Daiichi Sankyo JPY 249.96B 21.73B 2026-06
Eli Lilly USD 3.43B 496M 2026-06
Halozyme Therapeutics USD 57M 10.71M 2026-06
Heron Therapeutics USD 23.74M 605K 2025-12
Intrexon USD 10.31M 41K 2024-06
Ionis Pharmaceuticals USD 130.07M 20.92M 2026-06
Karyopharm Therapeutics USD 10.42M 861K 2026-03
Ligand Pharmaceuticals USD 29.12M 8.29M 2026-06
MacroGenics USD 9.71M 1.77M 2026-03
Neurocrine Biosciences USD 383.1M 64.6M 2026-06
Pfizer USD 3.41B 496M 2026-06
Regeneron Pharmaceuticals USD 662.1M 14.4M 2026-06
Rigel Pharmaceuticals USD 27.04M 1M 2024-09
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
Veracyte USD 55.71M 4.87M 2026-06